CTIS2023-504492-24-00招募中1 期
IMIMFCTL/ZOL_1
Parc De Salut Mar0 个研究点目标入组 8 人开始时间: 2023年4月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Tramadol Administered Orally to Healthy Subjects for the Improvement of its Detection in Biological Matrices in the Context of Anti-Doping Controlhealthy subjectsMedDRA version: 21.0Level: LLTClassification code: 10076471Term: Drug doping Class: 10022117CTIS2023-503799-25-00Parc De Salut Mar25
进行中（未招募）
1 期
Kidney cancerMetastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864MedDRA version: 22.0Level: HLTClassification code: 10038443Term: Renal failure and impairment Class: 10038359CTIS2023-505605-16-00Oncorena AB50
进行中（未招募）
1 期
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.o medical condition.CTIS2023-504516-15-00Bluepharma Industria Farmaceutica S.A.38
进行中（未招募）
1 期
/AMedDRA version: 18.0Level: LLTClassification code 10019515Term: Hemolytic uremic syndromeSystem Organ Class: 100000004851EUCTR2014-001740-38-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
进行中（未招募）
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participantsMental health disordersCTIS2024-512939-67-00Mindstate Design Labs Inc.68